The 2;13 chromosomal translocation occurs in most cases of the cancer alveolar rhabdomyosarcoma (ARMS), and juxtaposes the genes encoding the PAX3 and FKHR transcription factors. The resulting chimeric protein PAX3-FKHR is a potent transcriptional activator, and is hypothesized to function as a dominant acting oncogene. To investigate its biological function, PAX3-FKHR was transduced into three immortalized murine cell lines in either a constitutive or inducible manner. These cells only tolerate expression of low PAX3-FKHR levels, which is sufficient for transformation in NIH3T3 cells. In contrast, higher PAX3-FKHR levels, which are comparable to the endogenous level expressed in ARMS cells, result in growth suppression. To determine as to which PAX3 functional domains are needed for growth suppression and transformation, inactivating mutations were introduced into the paired box and homeodomain of PAX3-FKHR. In these experiments, the homeodomain is necessary for transformation, but not growth suppression; whereas the paired box is not required for transformation but mediates growth suppression. In summary, our findings demonstrate that the transforming and growth suppressive activities of PAX3-FKHR are dominant at different activity levels and are mediated by distinct functional domains. These findings are consistent with the hypothesis that distinct expression pathways are operative in these opposing phenotypic end points.
Introduction
Alveolar rhabdomyosarcoma (ARMS) is a pediatric soft-tissue sarcoma associated with the skeletal muscle lineage. In comparison with embryonal rhabdomyosarcoma (ERMS), the other major histological subtype of rhabdomyosarcoma, ARMS is clinically more aggressive and has a poorer prognosis (Tsokos et al., 1992) . Cytogenetic studies identified a specific chromosomal translocation t(2;13)(q35;q14) in the majority of ARMS cases (Barr, 1997) . This translocation juxtaposes the PAX3 and FKHR genes, and generates a PAX3-FKHR chimeric protein. PAX3 encodes a paired box transcription factor that plays a role in early myogenic development, whereas FKHR encodes a forkhead transcription factor involved in the insulin signaling and apoptotic control pathways (Matsuzaki et al., 2003) . The fusion product is a chimeric transcription factor containing the N-terminal PAX3 DNA binding domain and C-terminal FKHR transcription activation domain (Barr et al., 1993) .
A series of molecular biology studies indicate that the PAX3-FKHR fusion results in alterations at multiple biological levels. First, the PAX3-FKHR fusion protein is a more potent transcriptional activator compared to wild-type PAX3 (Bennicelli et al., 1996) . In addition, PAX3-FKHR mRNA and protein expression is elevated relative to wild-type PAX3 in ARMS cells (Davis and Barr, 1997) . Furthermore, PAX3-FKHR is located exclusively in nuclei, in contrast to wild-type FKHR whose subcellular localization is regulated by the AKTdependent signaling pathway (del Peso et al., 1999) . These multiple alterations ultimately result in high levels and high activity of a constitutively nuclear transcription factor and are hypothesized to contribute to its oncogenicity.
Studies involving overexpression or repression of PAX3-FKHR in cell lines support its oncogenic role. Expression of PAX3-FKHR in chicken embryo fibroblasts and NIH3T3 fibroblasts resulted in cellular transformation, as monitored by morphological changes, anchorage independent growth and focus formation (Lam et al., 1999) . In complementary studies, downregulation of PAX3-FKHR expression using a PAX3 antisense approach resulted in apoptosis in cultured ARMS cells (Bernasconi et al., 1996) . Together, these studies support a model in which gain of PAX3-FKHR function plays important roles in induction of cellular transformation and prevention of apoptosis.
Despite these studies providing evidence of PAX3-FKHR oncogenic activity, previous experiments in our and other laboratories have noted an inability for high efficiency stable expression of PAX3-FKHR in various common immortalized murine cell lines. To explore the basis of this phenomenon, in the current study we monitor the effect of PAX3-FKHR in various populations of immortalized murine cells and demonstrate that growth suppression occurs at the expression level that normally exists in ARMS cells. Furthermore, using an inducible system, we demonstrate that the PAX3-FKHR activity level is a crucial determinant of the cellular growth status in the immortalized murine cells, with oncogenic effects predominating at very low activity levels and growth suppression occurring at higher levels. Finally, we use mutated constructs to show that the two DNA binding domains of PAX3-FKHR, the paired box and the homeodomain, are functionally separable and involved in the control of growth suppression and transformation, respectively. These findings thus provide support for the hypothesis that separate gene expression pathways mediate these phenotypic activities.
Results

Expression of PAX3-FKHR causes cell death in murine cell lines
To investigate its biological function, PAX3-FKHR was subcloned into a retroviral vector (pK1) in which the cloning site is adjacent to an IRES and a puromycin resistance gene. This test construct or vector control (empty pK1) was transduced into three immortalized, nontransformed murine cell lines: NIH3T3 fibroblasts, C3H10T1/2 fibroblasts and C2F3 myoblasts. After 3 days of puromycin selection, which killed 99% of untransduced cells, the surviving cells were plated in puromycin-containing medium, and viable cells were counted daily by trypan blue exclusion using a hemocytometer. As shown in Figure 1a (inset), in all three lines, the control transduced cells increased 10-fold or more over a 4-day period. In contrast, for all three PAX3-FKHR-transduced cell lines, the cell numbers decreased five-to 10-fold during the first 4 days, indicating that the majority of cells underwent cell death. As shown for NIH3T3 cells, a small subset of surviving cells started to grow after 6 days and continued to grow for extended periods thereafter.
Based on our observations of cell death after PAX3-FKHR transduction, we hypothesized that high level expression of PAX3-FKHR protein may not be tolerated by these cell lines. To examine this hypothesis, Western blotting analysis was performed using total protein extracted from the cells after 3 days puromycin selection, and compared to that in the surviving, growing cells after 2 weeks puromycin selection. As shown in Figure 1b , in all three cell lines, the PAX3-FKHR expression level in cells after 3 days selection was comparable to the level in RH30 ARMS cells, and thus represented a physiologically appropriate level for our experiments. In contrast, very little PAX3-FKHR protein was detected in the murine cells after 2 weeks. In combination with the phenotypic data, we conclude that the initial high level of PAX3-FKHR expression, though comparable to the level expressed in ARMS tumor cells, was toxic to the immortalized murine cells and resulted in cell death. Only the small subset of cells with low levels of PAX3-FKHR expression could survive and grow, and hence this population became predominant once the cells expressing higher PAX3-FKHR levels died.
Expression level of PAX3-FKHR is critical for promoting cellular transformation
To investigate the relationship between PAX3-FKHR expression level and its transformation activity, a retroviral vector (MigR1) in which the cloning site is adjacent to an IRES and the GFP gene was used. After NIH3T3 cells were transduced with PAX3-FKHR, different fractions of GFP-positive cells were collected by FACS based on relative fluorescent intensity and divided into low, medium and high intensity fractions (Figure 2a) . Western blotting analysis revealed a direct (Figure 2a, inset) . Moreover, the transcriptional activity of the fractions, as measured by cotransfection analysis with a reporter construct containing PAX3 binding sites (6xPRS9), was also proportional to the expression level of PAX3-FKHR (Figure 2b ). To elucidate the relationship between the PAX3-FKHR expression level and transformation ability, anchorage independence was assessed by soft agar colony formation with aliquots of the GFPpositive cells. We observed that the transformation efficiency decreased as the fusion protein level increased, and thus there was an inverse correlation between transformation ability and PAX3-FKHR expression (Figure 2c) . Therefore, the low expression level of PAX3-FKHR is sufficient for cellular transformation, and may be the optimal level of PAX3-FKHR for cellular transformation.
Modulation of transcriptional function using estrogen-inducible system confirms the dual activities of PAX3-FKHR To better modulate PAX3-FKHR transcriptional activity in NIH3T3 cells, an estrogen inducible system was developed by linking a ligand-binding domain of estrogen receptor (ER) to the C-terminus of the PAX3-FKHR open reading frame. This modified murine ER ligand binding domain mutated on G525R is insensitive to estrogen which often exist in serum, yet sensitive to 4-hydroxytamoxifen (TMF), an estrogen analog (Littlewood et al., 1995) . The PAX3-FKHR-ER construct was cloned in a retroviral vector (pK1) in which the cloning site is adjacent to an IRES and puromycin resistance gene. In this inducible system, the fusion protein is bound to inhibitory proteins and sequestered as an inactive complex in the absence of ligand. With the addition and binding of the ligand TMF, the inhibitory proteins are released and the PAX3-FKHR-ER protein is able to move into areas of the cell where it is functional and able to act as a transcription factor. After this PAX3-FKHR-ER construct was transduced into NIH3T3 cells, and a population of PAX3-FKHR-ER expressing cells was selected, Western blotting analysis of cell lysates revealed higher levels of PAX3-FKHR-ER protein expression relative to the expression of PAX3-FKHR in RH30 ARMS cells (Figure 3a ). The ability of NIH 3T3 cells to tolerate high-level expression is consistent with the nonfunctional nature of the uninduced PAX3-FKHR-ER protein. The transcriptional activity, analysed by transient transfection of the 6xPRS9-luciferase reporter, was regulated by TMF in a dose-response manner ( Figure 3b ). It should be noted that, compared to the control vector-transduced cells, a low but elevated level of reporter activity was detected in PAX3-FKHR-ER expression cells in the absence of TMF. Increased activity was detected in the presence of 1 nM TMF and further increases were detected over a 100-fold dose range.
To study the consequence of PAX3-FKHR-ER induction, cell growth rate was analysed in the presence of a range of TMF concentrations. As predicted, the cell growth rates substantially decrease as the TMF concentration increases (Figure 3c ). In particular, there is a large decrease from 0.1 to 1 nM TMF in association with the large increase in PAX3-FKHR transcriptional activity ( Figure 3c ). These findings confirm that a high level of functional PAX3-FKHR protein slows down cell growth, as demonstrated in our previous experiments with constitutively expressed PAX3-FKHR protein. Finally, cellular transformation was evaluated using the soft agar colony assay. PAX3-FKHR-ER cells that were treated with 0 or 0.1 nM TMF generated comparable numbers of anchorage independent colonies, and the colony numbers then substantially decreased with further increasing TMF concentrations ( Figure 3d ). This finding again parallels the transcriptional activity curve. Taken together, our findings indicate that a very low activity level of PAX3-FKHR is sufficient for transformation, and further increases in this activity level cause growth suppression.
Effects of mutations at functional domains of PAX3-FKHR
To explore the involvement of the two N-terminal DNA binding domains of PAX3-FKHR, the paired box and homeodomain, on its oncogenic and growth suppressive activities, inactivating mutations were introduced by site-directed mutagenesis. Based on published results (Fortin et al., 1997) , glycine was mutated to serine at codon 48 to inactivate paired-box binding activity (G48S), and asparagine was mutated to alanine at codon 269 to inactivate homeodomain binding activity (N269A). In addition, a deletion of the FKHR transactivation domain was performed by removing 166 amino acids from the C-terminus of PAX3-FKHR (Lam et al., 1999) . Western blotting analysis verified the sizes of the mutated proteins (Figure 4d ). To verify the transcriptional effects of these mutants, wild-type PAX3-FKHR and each mutant was co-transfected with a paired-box or homeobox binding-site containing firefly luciferase reporter and renilla luciferase as transfection efficiency control reporter into NIH3T3 cells, and transcriptional activity was measured by the dual luciferase assay. Our results showed that the transcriptional activity of the PAX3-FKHR G48S mutant was greatly reduced when a PRS9 or CD19 reporter was used, which each contain paired box binding sites. However, the G48S mutation did not affect its transcriptional activity when the P3 luciferase reporter was used, which contains a homeobox binding-site ( Figure 4a ). The other N-terminal mutation, N269A, located within the homeobox, resulted in loss of transcriptional activity when tested with the P3 luciferase reporter, and enhanced activity compared to wildtype PAX3-FKHR when the PRS9 or CD19 reporter was used (Figure 4a ). The deletion mutation, which removed the C-terminal transactivation domain, caused a total loss of PAX3-FKHR transcriptional activity with the three tested reporter constructs. These findings are consistent with previous data indicating that these mutations inactivate their corresponding domain's transcriptional function without inactivating other domains. Examination of these mutants in the NIH3T3 transformation assay confirmed previously published findings that mutation of the homeodomain and deletion of the transcriptional activation domain result in decreased number of soft agar colonies, and thus these two domains but not the paired box are required for transformation activity of the fusion protein (Lam et al., 1999) (Figure 4b ). Interestingly, our findings indicate that the paired box mutant (G48S) exhibits more than 20-fold higher transformation ability compared to the wild-type fusion protein.
To similarly test the involvement of these PAX3-FKHR domains in growth suppression, we transduced the mutated constructs in pK1 into NIH3T3 cells. After 3 days puromycin selection, surviving cells were seeded in puromycin-containing medium, and counted at the indicated time points. The cell number decreased in cells transduced with the N269A homeodomain mutant similar to cells carrying wild-type PAX3-FKHR (Figure 4c ), indicating that this domain is not critical for growth suppression. However, cells transduced with the G48S paired box mutant revealed only a small degree of growth inhibition (Figure 4c ) during the time course (as noted, there were some floating but viable Transformation and growth suppression by PAX3-FKHR SJ Xia and FG Barr cells in the medium), providing evidence that the paired box is involved in the growth suppression activity of the fusion protein. In addition, removal of the transactivation domain also results in only a small degree of growth inhibition, confirming the role of the activation domain in the growth suppression activity.
As a second assay of growth suppression activity, we assessed the ability of cells to tolerate high level expression of the transduced mutant constructs. In earlier experiments, we demonstrated that NIH3T3 cells could not tolerate the high level of wild-type PAX3-FKHR expressed after 3 days puromycin selection and only cells expressing much lower levels survived after 2 weeks. To test the mutant constructs, NIH3T3 cells were transduced with each construct cloned in pK1, and protein was extracted from surviving cells after 3 days and 2 weeks puromycin selection. Our Western blotting analysis (Figure 4d ) demonstrated that, in the G48S mutant, PAX3-FKHR expression in 2 weeks culture is only slightly decreased compared to that in 3 days, supporting the hypothesis that this mutation caused loss of growth suppressive function. There is a significant decrease in expression of the N269A mutant in 2 weeks culture compared to 3 days, confirming a maintenance of growth suppression activity similar to the results for wild-type PAX3-FKHR (Figure 4d) . Finally, the expression level for the transactivation domain deletion mutant is not much different between 3 days and 2 weeks, confirming the loss of growth suppressive activity in this protein.
Discussion
Overexpression of various fusion oncoproteins causes growth suppression
The fusion protein PAX3-FKHR has been reported to be an oncogenic and antiapoptotic molecule that contributes to ARMS tumorigenesis through a gain of function mechanism. However, we demonstrate that expression of the PAX3-FKHR fusion protein at levels that are normally found in ARMS cells results in cell death or growth suppression in immortalized, nontransformed murine cell lines. Of interest, similar analysis of nononcogenic wild-type PAX3 in NIH3T3 cells demonstrated that it causes significantly less growth suppression (data not shown). In particular, the PAX3 protein level was not decreased after 2 weeks puromyocin selection, and growth curves showed only moderate growth suppression. These findings indicate that the cells are tolerant of the wild-type protein and specifically sensitive to the fusion protein. As noted, several others have also reported that other fusion proteins generated by chromosomal translocations have similar effect on cells. Burel et al. (2001) reported that AML1-ETO, generated by the 8;21 chromosomal translocation found in acute myeloid leukemia, caused myeloid cell growth arrest and blocked differentiation. Deneen and Denny (2001) found that the expression of EWS-FLI1, the fusion protein resulting from the 11;22 chromosomal translocation in Ewing's sarcoma, induced apoptosis and growth arrest in normal mouse embryonic cells. Therefore, this cell death and growth suppression phenomenon may exist widely for these fusion proteins associated with chromosomal translocations. It should be noted that, for some experiments, the results are not fully clear because of long selection times required to kill the untransfected cells, such as the 2 weeks generally needed to derive G418-resistant cells. During this 2 weeks period, any cells that expressed high levels of the fusion protein would be dead, and the end result is that the cells expressing low levels of the protein are often the only cells present at the end of the selection period.
Collaboration among two or more oncogenes or tumor suppressor genes
We report here that only low levels of PAX3-FKHR expression can be tolerated by the immortalized murine cells and a portion of the surviving cells were transformed as shown by the soft agar colony assay. Of note, when PAX3-FKHR was transfected into the ERMS cell line RD, multiple subclones were derived that expressed physiologic levels of PAX3-FKHR (Tomescu and Barr, personal communication), suggesting that some tumor environments may facilitate the tolerance of the cell to the toxic effects of PAX3-FKHR. This issue was further confirmed by the finding of partial resistance of PAX3-FKHR-ER-transduced RD cells when induced by TMF and scored by the colony formation assay (data not shown). In fact, the endogenous level of PAX3-FKHR in RH30, an ARMS cell line, is much higher than the level tolerated by the immortalized murine cells, suggesting that features within these ARMS cells attenuate the toxic effects and permit the cells to tolerate high level expression of PAX3-FKHR. In our search for candidate collaborating events, others and we have found that gene amplification occurs frequently in ARMS but not ERMS cells (Bridge et al., 2000 (Bridge et al., , 2002 . For example, the most frequently amplified chromosomal regions are 2p24 (involving MYCN) and 12q13-15 (involving MDM2 and CDK4) (Berner et al., 1996) . These alterations may result in overexpression of proteins that increase the tolerance of cells for PAX3-FKHR toxicity, thereby permitting PAX3-FKHR to exert its oncogenic effects. Several studies of cellular transformation and tumorigenesis have provided evidence to support the notion that introduction of oncogenes plus inactivation of tumor suppression gene are required to transform normal cells. For example, one report indicated that introduction of the H-Ras oncogene into primary human or rodent cells results in cellular senescence, but inactivation of p53 can prevent this outcome (Serrano et al., 1997) . Deneen and Denny (2001) also demonstrated that EWS-FLI1 caused apoptosis in primary mouse cells, but the apoptotic effect was attenuated in cells deficient in p16 pathway components.
Structure and functions of DNA binding domains in PAX3-FKHR PAX3-FKHR has two distinct DNA binding domains, the paired box and the homeodomain. The homeodomain of PAX3 is composed of three a-helices, and the third helix is the most conserved and important for the recognition of DNA and contact with the DNA major groove (Wilson et al., 1995) . Asn-269 is located in the third helical region, has direct contact with the major groove of the bound DNA, and is conserved among most PAX proteins (Kappen et al., 1993) . Previous studies have shown the N269A mutant of PAX3 decreases binding to a homeodomain-specific binding site (Fortin et al., 1997) , and our studies now show that the N269A mutant of PAX3-FKHR has decreased transcriptional activity as measured with a reporter containing a homeodomain specific binding site. In phenotypic studies with this PAX3-FKHR mutant, the N269A mutation abolishes transformation ability, but does not relieve growth suppression effect, suggesting a divergence in transcriptional targets associated with the two phenotypes.
Within the paired box, there are two subdomains, an N-terminal subdomain and a C-terminal subdomain, linked by a b-sheet linker (Xu et al., 1999) . The glycine at codon 48 is located in the N-subdomain, and has a direct contact with the DNA in its minor groove. This site is conserved through almost all PAX family members, and the mutation at this site has been detected in Waardenburg syndrome patients (Fortin et al., 1997) , suggesting the important role of Gly-48 in recognition, binding and/or transactivation functions. When the G48S mutation was introduced, PAX3 lost its DNA binding ability (Fortin et al., 1997) , and PAX3-FKHR lost its ability to transcribe genes with paired box binding sites (Figure 4a) , again proving the critical functional role of this amino acid in PAX3-FKHR function. In the growth suppression assay, our studies indicate that the G48S mutation partially relieves the growth suppressive effect of the PAX3-FKHR protein.
Therefore, there appears to be a role for the paired box but not the homeodomain in the transcriptional control of the growth suppression phenotype. Surprisingly, in the soft agar colony assay, the presence of the G48S mutation dramatically enhances the transforming ability of the PAX3-FKHR protein (Figure 4b ) compared to the wild-type PAX3-FKHR. From the reporter transfection data, this increased transformation activity cannot be attributed to a change in the transcriptional function of this PAX3-FKHR mutant. However, previous binding studies did note that, though the G48S mutation did not alter binding to a homeodomain binding site containing the TAATTGATTA motif, there was loss of binding to a half site containing the TAAT motif (Fortin et al., 1997) . Therefore, this mutation may have a cooperative effect on DNA binding specificity of the homeodomain and thereby affect a subset of its downstream targets. Finally, one additional important explanation for the observed increase in soft agar colony formation with the G48S mutation is attributable to the attenuated growth suppression of this mutant. Since there are more cells that can tolerate the growth suppressive effects of this oncoprotein, there are more cells that can potentially be transformed, and since our assay counts soft agar colony formation per plated cells, this mutant will be scored as having an apparent increase in transforming ability.
In summary, our data indicates that the transformation and growth suppression activities of PAX3-FKHR are separable in two different ways. First, transformation is dominant at low expression levels whereas growth suppression becomes dominant at higher expression levels. Second, the transformation activity is associated with the homeodomain whereas the growth suppression activity is at least partly associated with the paired box. In combination these findings are consistent with the hypothesis that the fusion protein regulates two different groups of downstream target genes or pathways to exert these two distinct phenotypic activities. Subsequent gene expression studies that utilize these inducible systems and DNA binding domain mutants will test this hypothesis, and thereby facilitate identification of genes and downstream targets involved in PAX3-FKHR-mediated transformation and growth suppression, as well as the steps involved in attenuation or abrogation of the growth suppression pathway.
Materials and methods
Plasmids and mutants
PAX3-FKHR was subcloned into modified MSCV retroviral vectors, pK1 and MigR1 (provided by Dr Warren Pear). These vectors contain an internal ribosome entry site (IRES) allowing translation of two open reading frames from one mRNA and a puromycin resistance gene for selection (pK1) or a green fluorescent protein (GFP) gene for cell sorting (MigR1). For transient transfection to measure transcriptional activity, PAX3-FKHR was subcloned into the pcDNA3 expression vector (Invitrogen) (Bennicelli et al., 1996) .
For an inducible system, a cDNA fragment containing the modified ER ligand-binding domain (provided by Dr T Littlewood) (Littlewood et al., 1995) was amplified using primers containing a SacII site (5 0 -TCCCCGCGGGGATC CACGAAATGAAATG-3 0 , 5 0 -TAACCGCGGCACTAGTA GGAGCTCTCAGA-3 0 , SacII sites are underlined). To subclone this fragment in-frame into the C-terminus of PAX3-FKHR, the stop codon of PAX3-FKHR was mutated by sitedirected mutagenesis (Stratagene) to create a SacII site (5 0 -CCTGCTCACTAACCCGCGGCCTGACACCCAGCT-3 0 , SacII site is underlined), and then the ER PCR fragment was ligated into the mutated PAX3-FKHR cDNA. The PAX3-FKHR-ER fragment was excised with SacI, and subcloned into the PK1 retroviral vector.
Mutations in the paired-box and homeobox of PAX3-FKHR in pBluescript, pcDNA3 and MigR1were generated by site-directed mutagenesis (Stratagene Quikchange). The mutated PAX3-FKHR fragments were excised from pBluescript and subcloned into pK1. For the deletion mutation, a stop codon was introduced at PAX3-FKHR codon number 671 to remove the FKHR transactivation domain. The deleted PAX3-FKHR cDNA fragment was generated by PCR and subcloned into various vectors. The primers for mutagenesis or PCR (mutated amino acid or stop codon are underlined) are:
(1) G48S: 5 0 -GGCGGCGTTTTTATCAACTCCAGGCCG CTGCCCAACCAC-3 0 (2) N269A: 5 0 -GTACAGGTCTGGTTTAGCGCCCGCCGT GCAAGATGGAGG-3 0 (3) Deletion: T7 primer and 5 0 -AAAGGAAAGAAGCGGCC GCAAATCAGCTGTTGGGCTGGGCAC-3 0 Luciferase reporter plasmids were constructed by inserting an isolated 6xPRS9 or 6xCD19 fragment upstream of the promoter in luciferase-containing reporter plasmids (from Dr M Busslinger). The 1xP3 luciferase-containing reporter plasmid was provided by Dr M Busslinger.
Cell culture, plasmid transfection and virus transduction NIH3T3 cells (from Dr C Denny), C3H10T1/2 fibroblasts (from Dr C Emerson) and C2F3 myoblasts (a C2C12 subclone provided by Dr H Blau) were cultured in DMEM containing 10% fetal bovine serum in a humidified incubator with 5% CO 2 at 371C. To prepare retrovirus, the test or control retroviral plasmid and PCL-10A1 retrovirus packaging vector (Imgenex) were co-transfected into 293T cells using Fugene 6 reagent (Roche-biochem) for virus production. After 2 days, virus was collected and the cells were transduced for 8 h in the presence of 8 mg/ml polybrene and then grown for 2-3 days before puromycin selection or fluorescence-activated cell sorting (FACS). For cell growth experiments, 1-3 Â 10 5 cells were plated per well in six-well plates, and then trypsinized at the indicated time points and counted by the trypan blue exclusion method (Invitrogen). The cell numbers were normalized for the first day cell numbers.
Western blotting and luciferase reporter assay
Whole-cell extracts were prepared using RIPA reagent (1 Â PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS with freshly added protease inhibitors, 1 mM PMSF, 1 mg/ml aprotinin, 2 mg/ml pepstatin, 1 mg/ml leupeptin), and then 40 mg protein or extract from 10 5 FACS sorted cells were fractionated on a 4-12% gradient precast Nupage gel (Invitrogen), and transferred onto a nitrocellulose membrane. The membrane was incubated for 1 h in PBS-Tween buffer (63 mM Na 2 HPO 4 , 15 mM NaH 2 PO 4 , 75 mM NaCl, 0.1% Tween, pH 7.4) with 5% dry milk for block nonspecific binding, and treated with either anti-PAX3 antibody or anti-actin antibody (Santa Cruz Biotechnology, Inc.) for 2 h followed by corresponding second antibody for 1 h. PAX3-FKHR or actin protein was visualized by chemiluminescence detection (Amersham).
For assay of transcriptional activity, 5 Â 10 4 NIH 3T3 cells were plated per well in 24-well plates, and 0.3 mg firefly luciferase reporter DNA (6xPRS9, 6xCD19, or 1xP3), 0.015 mg pRL-TK renilla luciferase DNA (Promega) as transfection efficiency control, and 0.015 mg test construct (PAX3-FKHR wild type or mutant in pcDNA3) were co-transfected into the cells (Fugene6, Roche-biochem) and incubated for 2 days. Transcriptional activity was measured for firefly and renilla luciferase by the dual luciferase assay (Promega), and was normalized for transfection efficiency.
Soft agar assay
After transducing MigR1 subclones into NIH 3T3 cells, 0.5-5 Â 10 4. cells were combined with 0.35% Noble agar in 1 Â Iscov's medium (Invitrogen) containing 10% fetal bovine serum, and plated on top of 0.7% bottom agar in the same medium. One more layer of top agar with medium and fetal bovine serum was added after 1 week, and then the plates were scored for colony formation after 3 weeks. The colony numbers were normalized for transduction efficiency assessed by FACS analysis of GFP expression after retroviral transduction.
